361 related articles for article (PubMed ID: 26590112)
1. Therapeutic targeting of BET protein BRD4 delays murine lupus.
Wei S; Sun Y; Sha H
Int Immunopharmacol; 2015 Dec; 29(2):314-319. PubMed ID: 26590112
[TBL] [Abstract][Full Text] [Related]
2. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
Yao L; Chen HP; Ma Q
Immunol Lett; 2014 Sep; 161(1):76-80. PubMed ID: 24837470
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
4. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
[TBL] [Abstract][Full Text] [Related]
5. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
6. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.
Jiang C; Zhao ML; Scearce RM; Diaz M
Arthritis Rheum; 2011 Apr; 63(4):1086-96. PubMed ID: 21225690
[TBL] [Abstract][Full Text] [Related]
7. Icariin alleviates murine lupus nephritis via inhibiting NF-κB activation pathway and NLRP3 inflammasome.
Su B; Ye H; You X; Ni H; Chen X; Li L
Life Sci; 2018 Sep; 208():26-32. PubMed ID: 30146016
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage.
Suarez-Alvarez B; Morgado-Pascual JL; Rayego-Mateos S; Rodriguez RM; Rodrigues-Diez R; Cannata-Ortiz P; Sanz AB; Egido J; Tharaux PL; Ortiz A; Lopez-Larrea C; Ruiz-Ortega M
J Am Soc Nephrol; 2017 Feb; 28(2):504-519. PubMed ID: 27436852
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL/lpr Mice.
Rohraff DM; He Y; Farkash EA; Schonfeld M; Tsou PS; Sawalha AH
Arthritis Rheumatol; 2019 Oct; 71(10):1681-1690. PubMed ID: 31106974
[TBL] [Abstract][Full Text] [Related]
10. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
Mannoor K; Matejuk A; Xu Y; Beardall M; Chen C
J Immunol; 2012 Apr; 188(8):3628-38. PubMed ID: 22407922
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
[TBL] [Abstract][Full Text] [Related]
12. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody therapy that targets phospholipid-binding protein delays lupus activity in MRL/lpr mice.
Mihaylova N; Bradyanova S; Chipinski P; Chausheva S; Kyurkchiev D; Tchorbanov AI
Scand J Immunol; 2020 Sep; 92(3):e12915. PubMed ID: 32533866
[TBL] [Abstract][Full Text] [Related]
14. A novel BAFF antagonist, BAFF-Trap, effectively alleviates the disease progression of systemic lupus erythematosus in MRL/lpr mice.
Yu C; Chen S; Zhou B; Zhang H; Su X; Luo Y; Yang L
Mol Immunol; 2021 Jan; 129():1-11. PubMed ID: 33254074
[TBL] [Abstract][Full Text] [Related]
15. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice.
Anders HJ; Vielhauer V; Eis V; Linde Y; Kretzler M; Perez de Lema G; Strutz F; Bauer S; Rutz M; Wagner H; Gröne HJ; Schlöndorff D
FASEB J; 2004 Mar; 18(3):534-6. PubMed ID: 14734643
[TBL] [Abstract][Full Text] [Related]
16. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.
Yan SX; Deng XM; Wang QT; Sun XJ; Wei W
Acta Pharmacol Sin; 2015 Nov; 36(11):1367-76. PubMed ID: 26456588
[TBL] [Abstract][Full Text] [Related]
17. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
18. (5R)-5-hydroxytriptolide ameliorates lupus nephritis in MRL/
Zhang LY; Li H; Wu YW; Cheng L; Yan YX; Yang XQ; Zhu FH; He SJ; Tang W; Zuo JP
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F769-F777. PubMed ID: 28100505
[TBL] [Abstract][Full Text] [Related]
19. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.
Patole PS; Gröne HJ; Segerer S; Ciubar R; Belemezova E; Henger A; Kretzler M; Schlöndorff D; Anders HJ
J Am Soc Nephrol; 2005 May; 16(5):1326-38. PubMed ID: 15772251
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.
Mishra N; Reilly CM; Brown DR; Ruiz P; Gilkeson GS
J Clin Invest; 2003 Feb; 111(4):539-52. PubMed ID: 12588892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
